Evidence map›Paper›PMID 32007141›Full record

ArticleLancet (London, England)2020

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Marc Brisson, Jane J Kim, Karen Canfell, Mélanie Drolet, Guillaume Gingras, Emily A Burger, Dave Martin, Kate T Simms, Élodie Bénard, Marie-Claude Boily and 15 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 485 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
485citing papers in PubMed, 16 pooled it
71.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

485 citing papers in PubMed, 16 syntheses or guidelines pooled it, 905 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Review
  18. Article
  19. Review
  20. Article

425 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 7 countries.

Marc BrissonCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Electronic address: marc.brisson@crchudequebec.ulaval.ca.
Jane J KimCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Karen CanfellCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
Mélanie DroletCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.
Guillaume GingrasCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.
Emily A BurgerCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
Dave MartinCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.
Kate T SimmsCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Élodie BénardCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.
Marie-Claude BoilyCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Stephen SyCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Catherine ReganCenter for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Adam KeaneCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Michael CaruanaCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Diep T N NguyenCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Megan A SmithCancer Research Division, Cancer Council NSW, Sydney, NSW, Australia; School of Public Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Jean-François LapriseCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada.
Mark JitCentre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, UK; Modelling and Economics Unit, Public Health England, London, UK; School of Public Health, University of Hong Kong, Hong Kong, China.
Michel AlaryCentre de recherche du CHU de Québec - Universite Laval, Québec, QC, Canada; Department of Social and Preventive Medicine, Universite Laval, Québec, QC, Canada; Institut national de santé publique du Québec, Québec, QC, Canada.
Freddie BraySection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
Elena FidarovaDepartment for the Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention, World Health Organization, Geneva, Switzerland.
Fayad ElsheikhDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Paul J N BloemDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Nathalie BroutetDepartment of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Raymond HutubessyDepartment of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Université Laval · CAWorld Health Organization · CHCancer Council NSW · AUUniversity of Sydney · AUCentre International de Recherche sur le Cancer · FRLondon Centre for Neglected Tropical Disease Research · GBUniversity of Hong Kong · HKUniversity of Oslo · NOUNSW Sydney · AU

Funding

Medical Research Council MR/R015600/1World Health Organization 001
6 · The paper itself

Abstract

backgroundThe WHO Director-General has issued a call for action to eliminate cervical cancer as a public health problem. To help inform global efforts, we modelled potential human papillomavirus (HPV) vaccination and cervical screening scenarios in low-income and lower-middle-income countries (LMICs) to examine the feasibility and timing of elimination at different thresholds, and to estimate the number of cervical cancer cases averted on the path to elimination.

methodsThe WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), which consists of three independent transmission-dynamic models identified by WHO according to predefined criteria, projected reductions in cervical cancer incidence over time in 78 LMICs for three standardised base-case scenarios: girls-only vaccination; girls-only vaccination and once-lifetime screening; and girls-only vaccination and twice-lifetime screening. Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assuming 90% coverage and 100% lifetime protection against HPV types 16, 18, 31, 33, 45, 52, and 58. Cervical screening involved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing from 45% (2023) to 90% (2045 onwards). The elimination thresholds examined were an average age-standardised cervical cancer incidence of four or fewer cases per 100 000 women-years and ten or fewer cases per 100 000 women-years, and an 85% or greater reduction in incidence. Sensitivity analyses were done, varying vaccination and screening strategies and assumptions. We summarised results using the median (range) of model predictions.

findingsGirls-only HPV vaccination was predicted to reduce the median age-standardised cervical cancer incidence in LMICs from 19·8 (range 19·4-19·8) to 2·1 (2·0-2·6) cases per 100 000 women-years over the next century (89·4% [86·2-90·1] reduction), and to avert 61·0 million (60·5-63·0) cases during this period. Adding twice-lifetime screening reduced the incidence to 0·7 (0·6-1·6) cases per 100 000 women-years (96·7% [91·3-96·7] reduction) and averted an extra 12·1 million (9·5-13·7) cases. Girls-only vaccination was predicted to result in elimination in 60% (58-65) of LMICs based on the threshold of four or fewer cases per 100 000 women-years, in 99% (89-100) of LMICs based on the threshold of ten or fewer cases per 100 000 women-years, and in 87% (37-99) of LMICs based on the 85% or greater reduction threshold. When adding twice-lifetime screening, 100% (71-100) of LMICs reached elimination for all three thresholds. In regions in which all countries can achieve cervical cancer elimination with girls-only vaccination, elimination could occur between 2059 and 2102, depending on the threshold and region. Introducing twice-lifetime screening accelerated elimination by 11-31 years. Long-term vaccine protection was required for elimination.

interpretationPredictions were consistent across our three models and suggest that high HPV vaccination coverage of girls can lead to cervical cancer elimination in most LMICs by the end of the century. Screening with high uptake will expedite reductions and will be necessary to eliminate cervical cancer in countries with the highest burden.

fundingWHO, UNDP, UN Population Fund, UNICEF-WHO-World Bank Special Program of Research, Development and Research Training in Human Reproduction, Canadian Institute of Health Research, Fonds de recherche du Québec-Santé, Compute Canada, National Health and Medical Research Council Australia Centre for Research Excellence in Cervical Cancer Control.

Indexed as

Papillomavirus VaccinesAdultDeveloping CountriesEarly Detection of CancerFeasibility StudiesFemaleHumansIncidenceIncomeMass ScreeningModels, BiologicalPapillomavirus InfectionsUterine Cervical NeoplasmsVaccinationPapillomavirus Vaccines

Identifiers

PMID32007141
PMCPMC7043009
OpenAlexW3003249044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.